Medication info
Triin Tablet 80/5/10mg

Triin Tablet 80/5/10mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Daewon Pharmaceutical Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
30 tablets (10 tablets x 3)/PTP
Approval status
Active

MFDS item code 201802229 · Approved 2018.05.30 · Insurance code 671806610

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, with or without food. If possible, it is recommended that you take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking a telmisartan/amlodipine combination and rosuvastatin as separate products, treatment may be switched to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before starting a telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with an individual component, switching directly to a telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is needed in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of telmisartan should not exceed 40 mg. ◦ Older patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving rosuvastatin, both before and during treatment, should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is effective for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, based on LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased to a maximum of 20 mg once daily. 2. Older patients: No dose adjustment is needed. 3. Patients with renal impairment: No dose adjustment is needed in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Since systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, the Cmax of rosuvastatin increased approximately 2.4-fold and its AUC increased approximately 1.3-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risks associated with the increase in rosuvastatin Cmax and monitor patients closely.

Ingredients

Manufacturer
Daewon Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein levels
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients with essential hypertension whose blood pressure is not adequately controlled, as well as for patients who need to take rosuvastatin for hyperlipidemia. The Telmisartan/Amlodipine combination improves blood pressure in patients with essential hypertension not adequately controlled by monotherapy. Rosuvastatin is used as an adjunct therapy in patients with primary hypercholesterolemia or mixed hyperlipidemia that are not controlled by diet and exercise. Additionally, it is an adjunct dietary therapy for patients with homozygous familial hypercholesterolemia and dysbetalipoproteinemia, delaying the progression of atherosclerosis by lowering total cholesterol and LDL cholesterol levels. Furthermore, it is effective in reducing the risk of stroke, myocardial infarction, and arterial revascularization procedures in elderly patients at high cardiovascular risk. This medication is used as an effective treatment for managing blood pressure and lipid levels.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. If possible, it is recommended that you take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking a telmisartan/amlodipine combination and rosuvastatin as separate products, treatment may be switched to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before starting a telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with an individual component, switching directly to a telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is needed in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of telmisartan should not exceed 40 mg. ◦ Older patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients receiving rosuvastatin, both before and during treatment, should follow a standard cholesterol-lowering diet and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is effective for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, based on LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased to a maximum of 20 mg once daily. 2. Older patients: No dose adjustment is needed. 3. Patients with renal impairment: No dose adjustment is needed in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Since systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, the Cmax of rosuvastatin increased approximately 2.4-fold and its AUC increased approximately 1.3-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risks associated with the increase in rosuvastatin Cmax and monitor patients closely.

Precautions

This medication can cause serious harm to the fetus and newborn during pregnancy, so if pregnancy is confirmed, use should be stopped immediately. Do not take this medication if you are allergic to any of its ingredients or similar medications. Patients with severely impaired liver function or problems with bile excretion should not take this medication. Patients with very poor kidney function or certain heart diseases should also avoid using this medication. Caution should be exercised when using this medication in elderly patients or in patients with slightly impaired liver function, very low blood pressure, or high potassium levels. In particular, patients with muscle problems or at high risk of myopathy should consult their doctor immediately if they experience muscle pain or weakness while taking this medication. This medication may interact with other drugs, so if you are taking any medications, you must inform your physician, and consultation is necessary during use. Regular tests for liver function and muscle-related symptoms should be conducted before and during use; if abnormal symptoms occur, inform healthcare personnel immediately. Women of childbearing potential should use appropriate contraceptive methods while taking this medication, and it is advisable not to take it while breastfeeding. Safety has not been established in children, and it is not recommended; however, it can be administered to the elderly without dosage adjustment, but with caution. In case of overdose, symptoms such as hypotension, cardiac arrhythmias, and worsened kidney function may appear, requiring immediate medical attention and appropriate treatment. Store this medication out of reach of children and do not transfer it to other containers.

Side effects

Viral upper respiratory tract infection, dyspnea, rectal bleeding, dyspepsia, atopic dermatitis, peripheral edema, chronic gastritis, various gastrointestinal disorders, hiatal hernia, dysuria, rhinitis, discomfort in the oropharynx, pulmonary disease, unspecified gastrointestinal disorder, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory reduction, movement disorders, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, headache, dizziness, orthostatic hypotension, back pain, edema, flushing, palpitations, fatigue, drowsiness, arrhythmia, bradycardia, chest pain, peripheral ischemia, syncope, postural hypotension, vasculitis, peripheral neuropathy, tremors, loss of appetite, constipation, dysphagia, pancreatitis, vomiting, gingival hyperplasia, allergic reactions, burning sensation, malaise, rigidity, weight gain, weight loss, arthralgia, muscle cramps, myalgia, erectile dysfunction, insomnia, neurodermatitis, depression, abnormal dreams, anxiety, depersonalization, epistaxis, angioedema, erythema multiforme, pruritus, rash, erythematous rash, papular rash, visual disturbance, conjunctivitis, diplopia, ocular pain, ear pain, frequent urination, urinary disorders, nocturia, dry mouth, increased sweating, hyperglycemia, thirst, leukopenia, purpura, thrombocytopenia, angioedema, headache, dizziness, weakness, cough, nausea, weakness, facial edema, lower extremity edema, thrombocytopenia, increased uric acid, liver function abnormalities, liver disease, acute renal failure, anemia, elevated CPK, anaphylactic reaction, tendon pain, rhabdomyolysis, hematuria, Stevens-Johnson syndrome, eosinophilia with systemic symptoms drug reaction syndrome, lupus-like syndrome, muscle rupture, memory loss, peripheral neuropathy, jaundice, hepatitis, depression, sleep disorders, interstitial lung disease, gynecomastia, liver failure, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to light, so it should be stored in a container that prevents light exposure. Additionally, it is advised to store the medication at room temperature between 1°C and 30°C. Avoid storing in excessively hot or cold places.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

30 tablets (10 tablets x 3)/PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.